Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Clinical studies with oral lipid based formulations of poorly soluble compounds

Authors Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Published 15 September 2007 Volume 2007:3(4) Pages 591—604

Dimitrios G Fatouros1, Ditte M Karpf1, Flemming S Nielsen1, Anette Mullertz1

Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark; 1Contributed equally to this work

Abstract: This work is an attempt to give an overview of the clinical data available on lipid based formulations. Lipid and surfactant based formulations are recognized as a feasible approach to improve bioavailability of poorly soluble compounds. However not many clinical studies have been published so far. Several drug products intended for oral administration have been marketed utilizing lipid and surfactant based formulations. Sandimmune® and Sandimmune Neoral® (cyclosporin A, Novartis), Norvir® (ritonavir), and Fortovase® (saquinavir) have been formulated in self-emulsifying drug delivery systems (SEDDS). This review summarizes published pharmacokinetic studies of orally administered lipid based formulations of poorly aqueous soluble drugs in human subjects. Special attention has been paid to the physicochemical characteristics of the formulations, when available and the impact of these properties on the in vivo performance of the formulation. Equally important is the effect of concurrent food intake on the bioavailability of poorly soluble compounds. The effect of food on the bioavailability of compounds formulated in lipid and surfactant based formulations is also reviewed.

Keywords: lipid formulations, poorly soluble compounds, pharmacokinetics, human clinical studies, lipophilic compounds, SEDDS, emulsions, food effect

Download Article [PDF] 

Readers of this article also read:

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Anand N, Sehgal R, Kanwar RK, Dubey ML, Vasishta RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:6355-6369

Published Date: 8 October 2015

A regenerative label-free fiber optic sensor using surface plasmon resonance for clinical diagnosis of fibrinogen

Nguyen TT, Bea SO, Kim DM, Yoon WJ, Park J-W, An SSA, Ju H

International Journal of Nanomedicine 2015, 10:155-163

Published Date: 27 August 2015

To what extent is clinical and laboratory information used to perform medication reviews in the nursing home setting? the CLEAR study

Mestres Gonzalvo C, Hurkens KPGM, de Wit HAJM, van Oijen BPC, Janknegt R, Schols JMGA, Mulder WJ, Verhey FR, Winkens B, van der Kuy PHM

Therapeutics and Clinical Risk Management 2015, 11:767-777

Published Date: 8 May 2015

Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions

Almer G, Summers KL, Scheicher B, Kellner J, Stelzer I, Leitinger G, Gries A, Prassl R, Zimmer A, Mangge H

International Journal of Nanomedicine 2014, 9:4211-4222

Published Date: 3 September 2014

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR

Vascular Health and Risk Management 2014, 10:237-246

Published Date: 25 April 2014

Spirituality in childhood cancer care

Lima NN, do Nascimento VB, de Carvalho SM, Neto ML, Moreira MM, Brasil AQ, Celestino Junior FT, de Oliveira GF, Reis AO

Neuropsychiatric Disease and Treatment 2013, 9:1539-1544

Published Date: 9 October 2013

Editorial - Clinical Epidemiology

Henrik Toft Sørensen

Clinical Epidemiology 2009, 1:17-18

Published Date: 27 February 2009

Targeting CD22 as a strategy for treating systemic autoimmune diseases

Thomas Dörner, David M Goldenberg

Therapeutics and Clinical Risk Management 2007, 3:953-959

Published Date: 15 November 2007